Biologic disease-modifying antirheumatic drugs such as tocilizumab and abatacept produce better treatment response in rheumatoid arthritis compared with tumour necrosis factor inhibitors (TNFi) when used in the first- or second-line setting and despite channelling of more severe patients to non-TNFi biologics, according to a study.
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.
Individuals with immunoglobulin A vasculitis (IgAV, otherwise known as Henoch-Schönlein purpura) – a type of small vessel vasculitis more common in children – have an increased risk of hypertension and chronic kidney disease (CKD), according to a retrospective analysis.
B-cell depletion therapy with rituximab leads to a significant delay in the onset of rheumatoid arthritis (RA) in individuals at high risk of developing the disease, demonstrating the pathogenetic role of B cells in the earliest prearthritis stage of autoantibody positive RA, according to data from the PRAIRI study.
Individuals with moderate-to-severe rheumatoid arthritis (RA) who had initially achieved sustained low disease activity (LDA)/remission with the selective Janus kinase inhibitor baricitinib 4 mg once daily appear to benefit from a dose stepdown to 2 mg, according to a substudy of the ongoing RA-BEYOND* trial.
The selective Janus kinase (JAK) inhibitor baricitinib shows an acceptable safety profile up to 5.5 years of long-term exposure in patients with moderate-to-severe active rheumatoid arthritis (RA), according to an integrated safety analysis.
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Reduced caloric intake results in a significant improvement in glucose metabolism and body-fat composition, including liver-fat content, according to a study. Changes in ferritin levels appear to mediate the striking reduction in liver fat.